Susan Bobulsky
Known title: Chief Commercial Officer, MRDCIK: 0001820885
Associated companies
Transaction History
| ADPT | ▼ Sell | Open Market | 6,444 | $193K | 10/6/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 1,195 | $32K | 9/15/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 3,000 | $75K | 8/10/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 1,299 | $31K | 7/30/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 5,000 | $115K | 7/16/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 487 | $11K | 7/1/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 5,000 | $103K | 6/25/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 5,000 | $95K | 6/11/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 11,000 | $198K | 6/4/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 41,338 | $544K | 3/11/2026 | View on chart |
| ADPT | ▲ Buy | Grant | 59,375 | $0 | 3/4/2026 | View on chart |
| ADPT | ▲ Buy | Grant | 62,500 | $0 | 3/4/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 26,023 | $182K | 3/5/2025 | View on chart |
| ADPT | ▲ Buy | Grant | 119,971 | $0 | 3/4/2025 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 5,000 | $10K | 10/8/2024 | View on chart |
| ADPT | ▼ Sell | Open Market | 6,016 | $21K | 3/5/2024 | View on chart |
| ADPT | ▼ Sell | Open Market | 6,975 | $24K | 3/5/2024 | View on chart |
| ADPT | ▲ Buy | Grant | 132,979 | $0 | 3/4/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.